NO993846D0 - Metode for deteksjon og lokalisering av maligne, humane tumorer - Google Patents

Metode for deteksjon og lokalisering av maligne, humane tumorer

Info

Publication number
NO993846D0
NO993846D0 NO993846A NO993846A NO993846D0 NO 993846 D0 NO993846 D0 NO 993846D0 NO 993846 A NO993846 A NO 993846A NO 993846 A NO993846 A NO 993846A NO 993846 D0 NO993846 D0 NO 993846D0
Authority
NO
Norway
Prior art keywords
detection
composition
relates
neurotensin
malignant tumors
Prior art date
Application number
NO993846A
Other languages
English (en)
Other versions
NO993846L (no
Inventor
J C Reubi
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Publication of NO993846D0 publication Critical patent/NO993846D0/no
Publication of NO993846L publication Critical patent/NO993846L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin
NO993846A 1997-02-03 1999-08-10 Metode for deteksjon og lokalisering av maligne, humane tumorer NO993846L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200297 1997-02-03
PCT/US1998/001964 WO1998033531A1 (en) 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours

Publications (2)

Publication Number Publication Date
NO993846D0 true NO993846D0 (no) 1999-08-10
NO993846L NO993846L (no) 1999-09-09

Family

ID=26146106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993846A NO993846L (no) 1997-02-03 1999-08-10 Metode for deteksjon og lokalisering av maligne, humane tumorer

Country Status (11)

Country Link
US (2) US6312661B1 (no)
EP (1) EP0968001B1 (no)
JP (1) JP2001511152A (no)
AT (1) ATE253381T1 (no)
AU (1) AU728712C (no)
CA (1) CA2279530C (no)
DE (1) DE69819478T2 (no)
HU (1) HUP0001316A3 (no)
IL (1) IL131386A0 (no)
NO (1) NO993846L (no)
WO (1) WO1998033531A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3340699B2 (ja) * 1998-06-05 2002-11-05 東京瓦斯株式会社 膵外分泌機能診断剤
US7232559B1 (en) 1999-06-04 2007-06-19 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
WO2001030398A2 (en) * 1999-10-22 2001-05-03 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
US7630907B2 (en) * 2001-10-30 2009-12-08 Biodose, Llc Algorithm and program for the handling and administration of radioactive pharmaceuticals
US8175890B2 (en) * 2001-10-30 2012-05-08 Biodose, Llc Pharmacy based method and algorithm for handling of radioactive pharmaceuticals and generating of reports therefrom
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20040039241A1 (en) * 2002-05-29 2004-02-26 Biodose Llc Integrated distribution and communication process and algorithm for providing, handling, distributing or generating reports regarding radioactive pharmaceuticals
AU2003259172A1 (en) * 2002-07-24 2004-02-09 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
GR1004637B (el) * 2003-04-04 2004-07-23 Βιομεντικααλαιφασαιενσισαανωνυμηαεταιριααφαρμακευτικωναπροιοντωναα Συνθεσηαβιολογικηακαιαπροκλινικηααξιολογησηααναλογωνανευροτενσινησα}@@bατροποποιημενωναμεαπαραγωγαατουᐏ@ϊ@τετρααζαενδεκανιουα}@ϊ@tetraazaundecanebακαιαεπισημασμενωναμεατεχνητιο@mα}αηαλλααραδιονουκλιδιαατουατεχνητιουbαη@καιαρηνιο@ϊϊα}΄ηααλλααραδιονουκλιδιαατουαρηνιουbαγιααεφαρμογηαστηναογκολογιαα
EP2474328A3 (en) * 2003-09-17 2012-07-18 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
US7507547B2 (en) * 2004-09-09 2009-03-24 University Of Massachusetts Screening assays for antioxidants and antiproliferative compounds
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
ES2538002T3 (es) 2009-01-07 2015-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
EP2454272B1 (en) * 2009-07-16 2017-08-23 IASON GmbH Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
JP7065567B2 (ja) 2014-06-10 2022-05-12 スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687680A1 (fr) * 1992-02-20 1993-08-27 Centre Nat Rech Scient Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee.
AU3967593A (en) * 1992-03-25 1993-10-21 Mallinckrodt Medical, Inc. Method of intraoperatively detecting and locating tumoral tissues
CA2086453A1 (en) * 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
JPH11514329A (ja) * 1994-02-18 1999-12-07 マリンクロット・メディカル・インコーポレイテッド 標識化ペプチド化合物
FR2720066B1 (fr) * 1994-05-20 1996-06-28 Rhone Poulenc Rorer Sa Peptides antagonistes de la neurotensine.
FR2722193B1 (fr) * 1994-07-08 1996-10-04 Sanofi Sa Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant
WO1996023527A1 (en) * 1995-02-03 1996-08-08 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours

Also Published As

Publication number Publication date
HUP0001316A2 (hu) 2000-09-28
DE69819478T2 (de) 2004-09-02
EP0968001A1 (en) 2000-01-05
US20020155064A1 (en) 2002-10-24
US6312661B1 (en) 2001-11-06
HUP0001316A3 (en) 2001-10-29
EP0968001B1 (en) 2003-11-05
JP2001511152A (ja) 2001-08-07
NO993846L (no) 1999-09-09
AU728712B2 (en) 2001-01-18
CA2279530C (en) 2009-04-28
DE69819478D1 (de) 2003-12-11
CA2279530A1 (en) 1998-08-06
AU6262298A (en) 1998-08-25
AU728712C (en) 2001-07-19
IL131386A0 (en) 2001-01-28
ATE253381T1 (de) 2003-11-15
WO1998033531A1 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
NO993846D0 (no) Metode for deteksjon og lokalisering av maligne, humane tumorer
Eder et al. Preclinical evaluation of a bispecific low‐molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer
US11547767B2 (en) 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen
CN101631801B (zh) 受体（sstr2）-选择性生长抑素拮抗剂
Tjuvajev et al. Iododeoxyuridine uptake and retention as a measure of tumor growth
EP3766893B1 (en) 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
Bonnet‐Duquennoy et al. Targeted radionuclide therapy of melanoma: anti‐tumoural efficacy studies of a new 131I labelled potential agent
US20060188441A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for PET imaging of EGFR expression in malignant tumors
Liu et al. 99mTc-labeled SWL specific peptide for targeting EphA2 receptor
N Eberle et al. Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions
Nagy et al. Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers
O'Byrne et al. Scintigraphic imaging of small-cell lung cancer with [111In] pentetreotide, a radiolabelled somatostatin analogue
Guo et al. A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
JPH04506343A (ja) ターゲッティング薬剤
ES2294818T3 (es) Procedimiento para reconocimiento y determinacion receptores gnrh y utilizacion de agonistas de gnrh y antagonistas de gnrh y otros ligandos receptor de gnrh para tratamiento tumores con receptores de gnrh,que provienen cerebro y/o sistema nervioso y/o meninges y/o sarcoma kaposi.
Nock et al. Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1–preclinical and first clinical results
Liu et al. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone
Hauck et al. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia
Arista et al. Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas
JP2002516882A5 (no)
JP2022517662A (ja) 腫瘍細胞外マトリックスにおける腫瘍性タンパク質に特異的なペプチドｐｅｔ／ｓｐｅｃｔプローブ
CN113316721A (zh) 用于靶向甲状腺髓样癌的组合物
Varshney et al. Targeting Bombesin Peptide Receptors for Cancer Imaging: Perspective in Prostate, Lung and Breast Cancer
WO1997031657A3 (en) Use of labelled cck-b receptor ligands for the detection and localization of malignant human tumors
ES2307325T3 (es) Metodo para aumentar la acumulacion en tejidos de compuestos raiomarcados.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application